-+ 0.00%
-+ 0.00%
-+ 0.00%

Genelux publishes corporate presentation highlighting Olvi-Vec late-stage ovarian cancer program focused on platinum sensitization

PUBT·08/13/2026 20:56:03
Listen to the news
Genelux publishes corporate presentation highlighting Olvi-Vec late-stage ovarian cancer program focused on platinum sensitization
  • Genelux highlighted its pivotal Phase 3 OnPrime/GOG-3076 trial of Olvi-Vec in platinum-resistant or -refractory ovarian cancer.
  • Topline Phase 3 results expected in 2H 2026; FDA alignment cited as potentially supporting traditional approval without a confirmatory trial.
  • Phase 2 VIRO-15 data cited: ORR 54% by RECIST; median PFS 11 months; median OS 15.7 months in 27 patients.
  • Systemic Olvi-Vec programs remain in enrollment for recurrent NSCLC Phase 2, recurrent SCLC Phase 1b/2; dose-finding updates expected in 2026.
  • Cash as of June 30, 2026 was about $19 million; quarterly operating cash burn averaged about $7 million; cash runway projected to Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.